Research programme: peptide cancer vaccine - PharmexaAlternative Names: GV 1003
Latest Information Update: 27 Feb 2008
At a glance
- Originator Pharmexa
- Mechanism of Action Telomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Feb 2008 Suspended - Preclinical for Cancer in Denmark (unspecified route)
- 27 Feb 2008 Suspended - Preclinical for Cancer in Sweden (unspecified route)
- 12 Sep 2006 Preclinical trials in Cancer in Denmark (unspecified route)